Related Experiment Videos
Localization of GD2-specific monoclonal antibody 3F8 in human osteosarcoma
J P Heiner1, F Miraldi, S Kallick
1Department of Orthopaedics, Rainbow Babies and Childrens Hospital, Cleveland, Ohio.
Abstract:
3F8 is a murine IgG3 monoclonal antibody specific for the antigen disialoganglioside GD2. Immunofluorescence staining showed strong binding of 3F8 to 15 of 17 human osteosarcomas, including primary and metastatic tumors. The targeting potentials of the native monoclonal antibody (3F8) and the F(ab')2 fragment (p-3F8) were tested in BALB/c athymic nude mice xenografted with human osteosarcomas. After radiolabeling with iodine using the chloramine T method, both 3F8 and p-3F8 retained immunoreactivities. The irrelevant IgG3 antibody TIB114 and its F(ab')2 fragment were used as negative controls. A Ewing's sarcoma xenograft, which was low in GD2 antigen, was also studied for comparison. Mice were sacrificed 1 day and 4 days after i.v. antibody injection. 3F8 and p-3F8 showed preferential accumulation in osteosarcoma over normal tissues with tumor:nontumor ratios of 2.7-58:1 and 1.4-82:1, respectively, on Day 1. These ratios improved to 10-163:1 and 6.0-75:1 on Day 4. The intact antibody 3F8 showed selective tumor uptake with a much higher percentage of injected dose per g than the fragment p-3F8 and exhibited a longer tissue half-life than p-3F8. These data indicate that anti-GD2 monoclonal antibodies may be useful for imaging and targeted therapy of human osteogenic sarcoma. The F(ab')2 fragment has the advantage of achieving favorable tumor:nontumor ratios sooner after antibody injection while the intact antibody shows better retention by tumor tissues.
Insights
The anti-disialoganglioside GD2 monoclonal antibody 3F8 and its fragment p-3F8 show promise for osteosarcoma imaging and therapy. Both demonstrated selective tumor accumulation, with the intact antibody offering better retention.
Area of Science:
- Oncology
- Immunology
- Radiochemistry
Background:
- Osteosarcoma is a primary bone cancer with limited treatment options.
- Disialoganglioside GD2 is a tumor-associated antigen overexpressed in various cancers, including osteosarcoma.
- Monoclonal antibodies targeting GD2 are being investigated for cancer therapy and imaging.
Purpose of the Study:
- To evaluate the targeting potential of the murine IgG3 monoclonal antibody 3F8 and its F(ab')2 fragment (p-3F8) against human osteosarcomas.
- To assess the in vivo biodistribution and tumor uptake of radiolabeled 3F8 and p-3F8 in a xenograft model.
- To compare the efficacy of the intact antibody versus its fragment for osteosarcoma targeting.
Main Methods:
- Human osteosarcoma xenografts in BALB/c athymic nude mice were used.
- The monoclonal antibody 3F8 and its F(ab')2 fragment p-3F8 were radiolabeled with iodine-131.
- Immunofluorescence staining confirmed GD2 expression on osteosarcoma cells.
- Biodistribution studies were performed by measuring radioactivity in tumors and normal tissues at 1 and 4 days post-injection.
Main Results:
- 3F8 and p-3F8 exhibited strong binding to human osteosarcomas.
- Both agents showed preferential accumulation in osteosarcoma tissues compared to normal tissues, with significant tumor:nontumor ratios.
- The intact antibody 3F8 demonstrated higher percentage of injected dose per gram and longer tissue half-life in tumors than the p-3F8 fragment.
- Tumor:nontumor ratios improved from Day 1 to Day 4 for both agents.
Conclusions:
- Anti-GD2 monoclonal antibodies, including 3F8 and its fragment, are effective in targeting human osteosarcomas.
- The intact antibody 3F8 offers superior tumor retention, while the F(ab')2 fragment p-3F8 achieves favorable tumor-to-normal tissue ratios earlier.
- These findings support the potential utility of 3F8 for imaging and targeted therapy of osteosarcoma.